{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=18", "query": { "condition": "Breast Adenocarcinoma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 700, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T03:59:42.608Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01177397", "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Diffuse Large B-Cell Lymphoma", "Glioblastoma Multiforme", "Hepatocellular Carcinoma", "Non-Small Cell Lung Cancer", "Neuroendocrine Tumors of Non-Pancreatic Origin", "Hormone Receptor-Positive Breast Cancer" ], "interventions": [ { "name": "CC-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2010-07-20", "completion_date": "2016-12-09", "has_results": true, "last_update_posted_date": "2022-12-13", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177397" }, { "nct_id": "NCT05012397", "title": "Milademetan in Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Head and Neck Carcinoma", "Cholangiocarcinoma", "Sarcoma", "Lung Adenocarcinoma", "Bladder Urothelial Carcinoma", "Stomach Adenocarcinoma", "Breast Cancer Invasive", "Ovarian Carcinoma", "Cervical Cancer", "Non Small Cell Lung Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Melanoma", "Pancreas Cancer", "MDM2 Gene Amplification", "Testicular Germ Cell Tumor", "Adrenocortical Carcinoma" ], "interventions": [ { "name": "RAIN-32", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rain Oncology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-11-01", "completion_date": "2023-10-15", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 14, "location_summary": "Palo Alto, California • Fort Myers, Florida • St. Petersburg, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05012397" }, { "nct_id": "NCT06299163", "title": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Peritoneal Carcinoma", "Endometrial Cancer", "Adenocarcinoma of Lung", "Triple Negative Breast Cancer", "Liposarcoma", "Leiomyosarcoma", "Mesothelioma, Malignant", "Adenocarcinoma - Gastroesophageal Junction (GEJ)", "Adenocarcinoma of the Stomach", "Melanoma, Malignant", "Renal Cell Carcinoma" ], "interventions": [ { "name": "NM32-2668", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Numab Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2024-05-01", "completion_date": "2025-04-18", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299163" }, { "nct_id": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Bladder Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Castration Resistant Prostate Cancer", "Colorectal Cancer", "Gastric/ Gastroesophageal Junction", "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Squamous Carcinoma of the Anal Canal" ], "interventions": [ { "name": "INCB106385", "type": "DRUG" }, { "name": "INCMGA00012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-02-03", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 8, "location_summary": "West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580485" }, { "nct_id": "NCT00310180", "title": "Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Adenocarcinoma", "Hormone Receptor Positive", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIB Breast Cancer AJCC v7" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 10273, "start_date": "2006-04-07", "completion_date": "2030-09-30", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 1160, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 723 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00310180" }, { "nct_id": "NCT02650635", "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Melanoma of the Skin", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Colorectal Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02-05", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650635" }, { "nct_id": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP546C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-05-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488676" }, { "nct_id": "NCT02453620", "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "OTHER" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-02-12", "completion_date": "2027-09-11", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 5, "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453620" }, { "nct_id": "NCT03979508", "title": "Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Ductal Carcinoma In Situ", "Breast Fibrocystic Change", "Breast Lobular Carcinoma In Situ", "Invasive Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2020-01-10", "completion_date": "2024-12-26", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03979508" }, { "nct_id": "NCT01849250", "title": "Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Benign Breast Neoplasm", "Ductal Breast Carcinoma In Situ", "Invasive Breast Carcinoma", "Lobular Breast Carcinoma In Situ", "Paget Disease of the Breast", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Docosahexaenoic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 65, "start_date": "2013-05", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-12-28", "last_synced_at": "2026-10-14T03:59:42.608Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849250" } ] }